|

Local Cecal Cancer - Optimization of Surgical Treatment

RECRUITINGN/ASponsored by Moscow Clinical Scientific Center
Actively Recruiting
PhaseN/A
SponsorMoscow Clinical Scientific Center
Started2022-09-01
Est. completion2025-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06121089

Summary

The purpose of this study is to determine the clinical efficacy, safety, and oncologic outcomes of ileocecal resection (ICR) with D3 lymphadenectomy compared to standard right hemicolectomy(RHC) for cecal cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* At least 18 years of age.
* ECOG status 0-2.
* Histologically confirmed adenocarcinoma of the colon.
* Clinical stage T1-3; N+; M0.
* The physical status from ASA classification I, II, III or IV.
* Written informed consent.

Exclusion Criteria:

* Synchronous or metachronous malignancy.
* Locally-advanced tumor (T\>3).
* Presence of distant metastases (M1).
* Complicated tumor: obstruction, perforation.
* Neoadjuvant chemotherapy.
* Medical contraindications for surgical treatment.
* Pregnancy or breast feeding.
* Medical or psychiatric conditions that compromise the patient's ability to give informed consent or comply with the study protocol.

Conditions3

CancerCecal NeoplasmsColonic Neoplasms Malignant

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.